Compare
Thermo Fisher Scientific Inc. vs Rockwell Automation, Inc
| Latest fiscal year | Thermo Fisher Scientific Inc. TMO | Rockwell Automation, Inc ROK |
|---|---|---|
| Year ended | 2025-12-31 | 2026-09-30 |
| Revenue | $44.56B | $8.99B |
| Revenue growth (YoY) | +3.9% | +7.8% |
| Gross margin | n/a | 50.0% |
| Operating margin | 17.4% | n/a |
| Net margin | 15.0% | 15.7% |
| Net income | $6.70B | $1.41B |
| EPS (Diluted) | $17.74 | $12.54 |
| Operating cash flow | $7.82B | $1.96B |
| Free cash flow | $6.29B | $1.70B |
| Cash & equivalents | $9.85B | $433.00M |
| Total assets | $110.34B | $11.27B |
| Total liabilities | n/a | n/a |
| Shareholders' equity | $53.41B | $3.55B |
| Return on year-end equity | 12.6% | 39.7% |
| Shares outstanding | n/a | 109.90M |
Revenue, most recent five fiscal years
| Fiscal year | Thermo Fisher Scientific Inc. | Rockwell Automation, Inc |
|---|---|---|
| Latest | $44.56B Ended 2025-12-31 | $8.99B Ended 2026-09-30 |
| 1 year earlier | $42.88B Ended 2024-12-31 | $8.34B Ended 2025-09-30 |
| 2 years earlier | $42.86B Ended 2023-12-31 | $8.26B Ended 2024-09-30 |
| 3 years earlier | $44.91B Ended 2022-12-31 | $9.06B Ended 2023-09-30 |
| 4 years earlier | $39.21B Ended 2021-12-31 | $7.76B Ended 2022-09-30 |